A clinical study of sacituzumab tirumotecan (sac-TMT) in people with bladder cancer (MK-2870-027)
This clinical study looks at an experimental medicine called sacituzumab tirumotecan (also known as sac-TMT) for adults with intermediate-risk non-muscle invasive bladder cancer. Non-muscle invasive bladder cancer means the cancer cells are only in the inner lining of the bladder and have not grown into the deeper muscle layer. 'Intermediate-risk' means there is a moderate chance the cancer could come back after treatment. Sac-TMT is a targeted treatment designed to find cancer cells and deliver medicine directly to them, aiming to harm fewer healthy cells. In this trial, researchers want to check the safety of sac-TMT, find the most effective dose, and see if it helps keep the cancer under control. Joining the trial involves regular hospital visits, receiving the medicine through a drip, and having standard monitoring tests.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
The bladder is an organ that collects and stores urine. In non-muscle invasive bladder cancer, cancer cells grow on the inner surface of the bladder wall without spreading into the deeper muscle. Doctors often classify this cancer by risk. Intermediate-risk means the cancer has a moderate chance of returning or growing after it has been removed, so extra treatment may be needed to keep it away.
This trial is testing a new medicine called sacituzumab tirumotecan (sac-TMT). It belongs to a modern group of cancer medicines called antibody-drug conjugates. You can think of this type of medicine as a guided missile: it searches for specific proteins on the surface of bladder cancer cells, attaches to them, and releases a cancer-fighting medicine right inside the cell. The goal is to destroy cancer cells while causing less damage to healthy tissue.
This study combines early trial phases to learn two main things: how safe the treatment is and how well it works. Doctors will track any side effects to find the best dose and measure whether the medicine lowers the chance of the cancer coming back. The findings could help provide a new treatment option for people living with bladder cancer in the future.
النقاط الرئيسية
- The trial tests a new targeted drug called sac-TMT for non-muscle invasive bladder cancer.
- It is aimed at adults aged 18 and over with intermediate-risk cancer.
- The treatment is given via a drip in hospital under close medical supervision.
- The main aims are to test safety, find the best dose, and see if it prevents cancer returning.
- Participation is entirely voluntary, and you can withdraw at any time.
من قد يكون مؤهلاً؟
This trial is open to adults aged 18 and older who have been diagnosed with intermediate-risk non-muscle invasive bladder cancer. Before taking part, doctors will confirm the stage and risk level of your cancer using routine tests and tissue samples.
You will need to be well enough to carry out daily activities and attend regular hospital appointments. The study team will review your general health, including how well your kidneys, liver, and heart are working, to make sure it is safe for you to take part.
You may not be able to join if your bladder cancer has spread into the muscle layer or to other parts of the body. Having certain other active medical conditions, severe infections, or receiving certain recent cancer treatments might also mean this trial is not suitable for you.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- عمري 18 عامًا أو أكثر.
- I have been diagnosed with intermediate-risk non-muscle invasive bladder cancer.
- My cancer has not spread into the deeper muscle of my bladder.
- I am well enough to attend regular hospital appointments.
- I am open to receiving treatment through a vein at the clinic.
ماذا يتضمن المشاركة؟
If you take part, you will receive sacituzumab tirumotecan as an infusion into a vein (through a drip) at a hospital clinic. How often you receive the medicine and the length of each visit will depend on the exact study schedule, which the research team will explain to you beforehand.
You will have regular health checks throughout the study. These typically include blood and urine tests, physical examinations, and heart checks. You will also have cystoscopies (where a doctor uses a thin, flexible camera to look inside your bladder) and occasional scans to see how your bladder is responding to the treatment.
Your participation may last several months to a couple of years, depending on how well the medicine works for you and how you feel. After treatment ends, the study team will continue to check on your health through follow-up visits or phone calls.
المخاطر والفوائد المحتملة
المواقع (3)
- —غير مؤكدإسبانيا
- —غير مؤكدفرنسا
- —غير مؤكدهولندا
أسئلة شائعة
What does non-muscle invasive bladder cancer mean?
It means the cancer is only located in the inner lining of the bladder and has not spread into the deeper muscle wall.
How is the trial medicine given?
It is usually given through a small tube into a vein (an intravenous infusion or drip) at the hospital clinic.
Will taking part cost me anything?
No, the trial medicine and study-related tests are provided free of charge, and some trials offer help with travel expenses.
هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟
Yes, you can leave the study at any point. Your decision will not affect the quality of your standard medical care.
Will I still have camera checks (cystoscopies) of my bladder?
Yes, regular camera checks inside the bladder are essential to monitor whether the cancer has returned or changed.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.